Equities

Finch Therapeutics Group Inc

FNCH:PKL

Finch Therapeutics Group Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)12.05
  • Today's Change0.600 / 5.24%
  • Shares traded4.46k
  • 1 Year change+225.68%
  • Beta1.3025
Data delayed at least 15 minutes, as of Nov 22 2024 20:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 113 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. Its assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.

  • Revenue in USD (TTM)0.00
  • Net income in USD-14.17m
  • Incorporated2017
  • Employees18.00
  • Location
    Finch Therapeutics Group Inc75 State Street, Suite 100BOSTON 02109United StatesUSA
  • Phone+1 (617) 229-6499
  • Fax+1 (302) 636-5454
  • Websitehttps://finchtherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Neurosense Therapeutics Ltd0.00-7.51m17.52m16.00---------0.4392-0.43920.00-0.09430.00----0.00-154.72---470.03----------------------18.10------
Kazia Therapeutics Ltd (ADR)14.67k-13.30m17.82m12.00--0.1677--1,215.24-80.70-80.700.079634.360.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
MEI Pharma Inc0.00-46.60m18.52m28.00--0.7446-----6.99-6.990.003.730.00----0.00-72.25-21.09-79.28-23.99-------72.23----0.00--33.7667.75155.84---49.68--
NanoViricides Inc0.00-9.45m18.69m7.00--1.86-----0.7579-0.75790.000.71880.00----0.00-69.61-43.88-76.92-46.26------------0.00------3.43--16.23--
Palatin Technologies, Inc.2.38m-32.35m18.77m30.00------7.87-1.98-1.980.1434-0.39320.3252----79,470.34-441.31-55.28---69.0895.90---1,357.06-1,359.14---------7.49-40.52-23.71--3.31--
Unity Biotechnology Inc0.00-19.05m19.21m19.00--1.36-----1.14-1.140.000.83940.00----0.00-32.73-47.21-38.49-53.51-------6,395.92----0.00---100.00--10.36---61.28--
Eom Pharmaceutical Holdings Inc0.00-4.93m19.26m3.00---------0.0435-0.04350.00-0.0212------0.00---126.34---171.37------------7.41-------254.37------
Finch Therapeutics Group Inc0.00-14.17m19.35m18.00--1.36-----8.82-8.820.008.860.00-------25.20---28.80--------------0.00---87.57--34.80------
Mira Pharmaceuticals Inc0.00-11.24m19.51m3.00--6.01-----0.7287-0.72870.000.21970.00----0.00-169.22---191.76-------------3.320.00-------69.77------
Goldenwell Biotech Inc940.00-137.11k19.80m----5,169.71--21,063.83-0.0014-0.00140.000010.000040.00480.0031-----69.82---70.29--42.55---14,586.17--21.43--0.00---95.10--88.13------
Spruce Biosciences Inc7.10m-39.43m19.96m22.00--0.3866--2.81-0.9598-0.95980.17281.250.0798----244,862.10-44.28-41.24-55.51-46.49-----555.23-1,774.39---121.120.0399-------3.77------
Neurobo Pharmaceuticals Inc0.00-27.73m20.42m8.00--1.58-----4.77-4.770.001.500.00----0.00-114.20-95.57-159.68-135.64------------0.00------10.72--75.54--
GlycoMimetics Inc10.00k-39.74m20.43m35.00--1.80--2,042.85-0.6165-0.61650.00020.17640.0003--0.0836285.71-115.34-43.60-136.58-47.82-----397,350.50-2,243.52----0.00---86.67--20.97---29.82--
Kairos Pharma Ltd0.00-2.74m20.55m----6.17-----0.2279-0.22790.000.25940.00-------92.10---264.70-------------2.610.0409-------72.57------
Aeon Biopharma Inc0.00-350.57m20.95m5.00---------9.61-9.610.00-0.81060.00----0.00-3,242.54----------------2.94---------631.85------
Data as of Nov 22 2024. Currency figures normalised to Finch Therapeutics Group Inc's reporting currency: US Dollar USD

Institutional shareholders

0.25%Per cent of shares held by top holders
HolderShares% Held
Aperture Investors LLCas of 30 Sep 20213.96k0.25%
Guggenheim Partners Investment Management LLCas of 31 Aug 20241.000.00%
Bain Capital Public Equity LPas of 08 Jun 20230.000.00%
Lake Street Advisors Group LLCas of 30 Sep 20240.000.00%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.